|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:academic_programs
|
gptkb:Yes
|
|
gptkbp:acquired
|
gptkb:Cook_Pharmica
Aptar Group's drug delivery business
|
|
gptkbp:acquisition
|
gptkb:Juniper_Pharmaceuticals
gptkb:Paragon_Bioservices
|
|
gptkbp:biologics_commercialization
|
gptkb:Yes
|
|
gptkbp:biologics_development
|
gptkb:Yes
|
|
gptkbp:biologics_manufacturing
|
gptkb:Yes
|
|
gptkbp:biopharmaceutical_innovation
|
gptkb:Yes
|
|
gptkbp:biopharmaceutical_services
|
gptkb:Yes
|
|
gptkbp:cell_and_gene_therapy_solutions
|
gptkb:Yes
|
|
gptkbp:ceo
|
gptkb:Alfredo_C._Gangotena
|
|
gptkbp:clinical_supply_chain_solutions
|
gptkb:Yes
|
|
gptkbp:clinical_supply_services
|
gptkb:Yes
|
|
gptkbp:clinical_trial
|
gptkb:Yes
|
|
gptkbp:clinical_trial_efficiency
|
gptkb:Yes
|
|
gptkbp:collaborations
|
gptkb:Yes
|
|
gptkbp:contract_services
|
gptkb:Yes
|
|
gptkbp:customer_base
|
Global
|
|
gptkbp:employees
|
over 14,000
|
|
gptkbp:expansion_plans
|
gptkb:Yes
|
|
gptkbp:financial_performance
|
gptkb:Strong
|
|
gptkbp:focus
|
gptkb:Gene_Therapy
gptkb:Cell
Biologics
|
|
gptkbp:founded
|
gptkb:2007
|
|
gptkbp:global_manufacturing_network
|
gptkb:Yes
|
|
gptkbp:global_presence
|
gptkb:Yes
|
|
gptkbp:headquarters
|
gptkb:Somerset,_New_Jersey
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Catalent Pharma Solutions
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:injectable_drug_delivery
|
gptkb:Yes
|
|
gptkbp:innovation
|
gptkb:Yes
|
|
gptkbp:investment
|
gptkb:Yes
|
|
gptkbp:involved_technology
|
gptkb:Yes
|
|
gptkbp:is_a_platform_for
|
gptkb:Yes
|
|
gptkbp:manufacturing_capabilities
|
gptkb:Yes
|
|
gptkbp:market_access_solutions
|
gptkb:Yes
|
|
gptkbp:market_position
|
Leader in drug development and delivery
|
|
gptkbp:operates_in
|
over 30 facilities
|
|
gptkbp:oral_drug_delivery
|
gptkb:Yes
|
|
gptkbp:packaging
|
gptkb:Yes
|
|
gptkbp:parent_company
|
gptkb:Catalent,_Inc.
|
|
gptkbp:partnership_with_biotech_firms
|
gptkb:Yes
|
|
gptkbp:partnership_with_fda
|
gptkb:Yes
|
|
gptkbp:partnership_with_healthcare_providers
|
gptkb:Yes
|
|
gptkbp:partnerships
|
Various pharmaceutical companies
|
|
gptkbp:patient_adherence_solutions
|
gptkb:Yes
|
|
gptkbp:patient-centric_solutions
|
gptkb:Yes
|
|
gptkbp:patient-focused_services
|
gptkb:Yes
|
|
gptkbp:product
|
gptkb:Yes
|
|
gptkbp:product_quality
|
gptkb:Yes
|
|
gptkbp:reach
|
gptkb:Yes
|
|
gptkbp:regulatory_compliance
|
gptkb:Yes
|
|
gptkbp:regulatory_expertise
|
gptkb:Yes
|
|
gptkbp:research_and_development
|
gptkb:Yes
|
|
gptkbp:revenue
|
$3 billion (2021)
|
|
gptkbp:safety
|
gptkb:Yes
|
|
gptkbp:safety_and_efficacy
|
gptkb:Yes
|
|
gptkbp:services
|
Drug Development
Commercialization
Drug Delivery
|
|
gptkbp:softgel_technology
|
gptkb:Yes
|
|
gptkbp:stock_symbol
|
CTLT
|
|
gptkbp:supply_chain
|
gptkb:Yes
|
|
gptkbp:supply_chain_agility
|
gptkb:Yes
|
|
gptkbp:sustainability_initiatives
|
gptkb:Yes
|
|
gptkbp:traded_on
|
gptkb:New_York_Stock_Exchange
|
|
gptkbp:treatment
|
gptkb:Yes
|
|
gptkbp:type_of_care
|
gptkb:Yes
|
|
gptkbp:website
|
www.catalent.com
|
|
gptkbp:bfsParent
|
gptkb:Catalent
|
|
gptkbp:bfsLayer
|
6
|